Travere Therapeutics (TVTX) Operating Margin (2016 - 2025)
Historic Operating Margin for Travere Therapeutics (TVTX) over the last 13 years, with Q3 2025 value amounting to 15.12%.
- Travere Therapeutics' Operating Margin rose 1043900.0% to 15.12% in Q3 2025 from the same period last year, while for Sep 2025 it was 20.91%, marking a year-over-year increase of 1547200.0%. This contributed to the annual value of 138.88% for FY2024, which is 1283700.0% up from last year.
- As of Q3 2025, Travere Therapeutics' Operating Margin stood at 15.12%, which was up 1043900.0% from 11.05% recorded in Q2 2025.
- In the past 5 years, Travere Therapeutics' Operating Margin registered a high of 53.62% during Q4 2021, and its lowest value of 336.53% during Q1 2024.
- In the last 5 years, Travere Therapeutics' Operating Margin had a median value of 125.11% in 2024 and averaged 164.08%.
- Its Operating Margin has fluctuated over the past 5 years, first soared by 2861500bps in 2021, then tumbled by -3491400bps in 2022.
- Quarter analysis of 5 years shows Travere Therapeutics' Operating Margin stood at 53.62% in 2021, then crashed by -651bps to 295.52% in 2022, then rose by 29bps to 209.13% in 2023, then skyrocketed by 61bps to 81.21% in 2024, then soared by 119bps to 15.12% in 2025.
- Its Operating Margin stands at 15.12% for Q3 2025, versus 11.05% for Q2 2025 and 52.21% for Q1 2025.